Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Shareholder Meeting (2004)
19 slides from Neurizon Therapeutics's shareholder meeting presentation, Dec 22, 2004
Slide 1: PharmAust Limited: Annual General Meeting
PHARMAUST LIMITED: ANNUAL GENERAL MEETING Presented by: Dr Paul D’Sylva Chairman
Slide 2: Chairman's Address
CHAIRMAN’S ADDRESS
Slide 3: PharmAust History
PHARMAUST History October 2001 Listed on ASX. July 2003 New Board of Directors formed. Rights issue completed. Oct 2003 Following consolidation of existing assets, $840,000 raised in private placement. Oct 2003 Epichem Project ADDED to EHO’s R&D portfolio. Nov 2003 EHO makes key appointments to Epic
Slide 4: PharmAust Business Model
PharmAust Business Model PharmAust Ltd Vertically Integrated Pharmaceutical Company Chair: Dr Paul D'Sylva MD: Mr Bryant McLarty Epichem Pty Ltd PharmAust Manufacturing Pty Ltd Medicinal and Synthetic Chemistry Generic Pharmaceuticals Chair: Dr John Horton Chair: Dr Paul D'Sylva MD: Dr Wayne Best CE
Slide 5: PharmAust Business Model: Pharmaceutical Value Chain
PharmAust Business Model Pharmaceutical Value Chain Pharmaust
Slide 6: Epichem Pty Ltd Global Markets
Epichem Pty Ltd 6 5.5 Global Markets 5 4.5 • Global market for drug outsourcing is US$3 billion pa 4 3.5 • Global markets forecast to more than double over 5 years 3 2.5 • Untapped market in Asia- Pacific region 2 •Epichem is a ‘one-of-a kind’ 1.5 in the region 1 0.5 • Worldwide shortage of skilled
Slide 7: Epichem Pty Ltd
Epichem Pty Ltd • Epichem boasts Australia’s leading medicinal chemists • State-of-the-art facility completed February 2004 • Client contracts signed and $$ revenues achieved Epichem’s new facilities at Murdoch University, Western Australia
Slide 8: Epichem's People
Epichem’s People • Excellent commercial experience running one of only a handful of contract synthesis businesses worldwide • Unique, dynamic group • Ownership incentive Dr John Horton - Epichem Chairman Extensive pharmaceutical experience. Senior positions held within GlaxoSmith Kline. Currently wo
Slide 9: From Drug Discovery to Drug Production
From Drug Discovery to Drug Production PharmAust Manufacturing Pty Ltd ‘Meeting Australasia’s drug production needs’ Ownership: 100% PAA Focus: Production, distribution and marketing of OTC, patent-expired PBS medicines, and selected therapeutic hospital lines to Australia. Key Market: Lucrative gen
Slide 10: PharmAust Domestic Markets
Pharmaust Domestic Markets 6 5.5 • The Australian market for PBS 5 drugs is now some AU$6b pa and growing steadily. 4.5 4 • There are an unprecedented number of medicines coming off 3.5 patent in Australia over the next 3 3 years. 2.5 • PharmAust Man. can capitalise 2 on Epichem’s medicinal chemistr
Slide 11: The Path to PharmAust Manufacturing
The Path to PharmAus Manufacturing • 1970: Chemists Les Ramsay and William Prie spinout Ramprie Labs from Fauldings • 1985: Establishes GMP manufacturing facility on its own 1 acre sight in Welshpool, Perth, Western Australia. • 2003: Holds licenses to manufacture 95 registered and listed products o
Slide 12: Ramprie Laboratories
Ramprie Laboratories • Ramprie boasts a long history of pharmaceutical production • State-of-the-art facility aimed to be complete December, 2004 • Client contracts in place FAL – Signature range & Black & Gold, Surf Life Saving Australia, WA & QLD Health Departments Ramprie’s new facilities at its
Slide 13: PharmAust Manufacturing business strategy is three-fold
PharmAust Manufactuing PharmAust Man.’s business strategy is three-fold • Produce, market and distribute generic pharmaceuticals products for which it has TGA licenses (circa 95) in Australia. • In collaboration with Epichem, formulate, produce, market and distribute identified high-value PBS patent
Slide 14: Target Pharmaceutical Markets
Target Pharmaceutical Markets • Prescription Medicines AU$6b Govt subsidised – Patent-expired PBS drugs – Hospitals – Patent-expired and protected non PBS drugs • OTC Medicines AU$2b Generic Market Share PharmAust 4% Source: Company Reports, Deutsche Bank AG Estimates April 2001
Slide 15: High Value Prescription Lines: Simvastatin
High Value Prescription Lines Simvastatin 2003-2004 • 5.4 million prescriptions • Total revenue exceeds $360 million • Serum Lipid reducing agents have seen over $100 million growth • Patent expires July 2005
Slide 16: High Value Prescription Lines: Omeprazole
High Value Prescription Lines Omeprazole 2003- 2004 • 3.7 million prescriptions • Total revenue $190 million • Drugs for stomach acid related disorders have experienced over $65 million growth • Market is expanding into off- prescription availability such as Zantac® • Patent has expired
Slide 17: Over the Counter Medication: Loratadine
Over the counter medication Loratadine 2001 • Third largest selling drug in the world – antihistamine Claratyne® • Total world sales in 2000 of US $3 billion • Patent due to expire July 2006
Slide 18: Comparative Analysis
Comparative Analysis Market Cap at Oct 04 Oct 04 Market Company Name Notes Listing ($m) Float Date Issue Price Price Cap ($m) CAG Lipa Pharmaceuticals $ 135 Jul-04 $ 1.50 $ 2.27 $ 204 962% Genepharm Australia $ 38 Oct-04 $ 0.50 $ 0.69 $ 53 183% Arrow Pharmaceuticals $ 173 Oct-02 $ 2.75 $ 11.45 $ 722
Slide 19: Summary
Summary • PharmAust has corporatised the largest public medicinal chemistry laboratory in Australia, which services a $4b global market; • PharmAust has the rights to acquire a well-established generic pharmaceutical manufacturing company, which services a domestic OTC market of $2b; • PharmAust has